Joseph Stringer
Stock Analyst at Needham
(4.33)
# 329
Out of 5,135 analysts
314
Total ratings
47.65%
Success rate
19.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $510 | $332.68 | +53.30% | 25 | Feb 12, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $140 → $170 | $152.74 | +11.30% | 10 | Feb 11, 2026 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $7.83 | +78.80% | 19 | Feb 9, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $29 → $28 | $22.20 | +26.13% | 21 | Jan 13, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $145 → $148 | $101.30 | +46.10% | 29 | Jan 9, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $56.17 | +95.83% | 18 | Jan 7, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $78 → $90 | $82.22 | +9.46% | 25 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $65 | $72.83 | -10.75% | 19 | Oct 27, 2025 | |
| MRNA Moderna | Reiterates: Hold | n/a | $46.60 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $30.98 | +12.98% | 24 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $11.88 | +135.69% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $5.06 | +117.39% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $470.31 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.32 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.25 | +700.00% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $23.19 | +59.55% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $19.17 | -6.10% | 2 | Aug 24, 2021 |
Alnylam Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $529 → $510
Current: $332.68
Upside: +53.30%
Gilead Sciences
Feb 11, 2026
Maintains: Buy
Price Target: $140 → $170
Current: $152.74
Upside: +11.30%
Vir Biotechnology
Feb 9, 2026
Reiterates: Buy
Price Target: $14
Current: $7.83
Upside: +78.80%
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Buy
Price Target: $29 → $28
Current: $22.20
Upside: +26.13%
Rhythm Pharmaceuticals
Jan 9, 2026
Maintains: Buy
Price Target: $145 → $148
Current: $101.30
Upside: +46.10%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $56.17
Upside: +95.83%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $78 → $90
Current: $82.22
Upside: +9.46%
Avidity Biosciences
Oct 27, 2025
Downgrades: Hold
Price Target: $65
Current: $72.83
Upside: -10.75%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $46.60
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $30.98
Upside: +12.98%
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $11.88
Upside: +135.69%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $5.06
Upside: +117.39%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $470.31
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.32
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.25
Upside: +700.00%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $23.19
Upside: +59.55%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $19.17
Upside: -6.10%